Business Context and Reporting Period
This Form 8-K was filed by Hancock Jaffe Laboratories, Inc. (HJLI) on April 14, 2020. The filing addresses a notice of potential delisting from The Nasdaq Stock Market LLC due to non-compliance with continued listing rules. Note: The input metadata references "Envveno Medical Corp," but the filing text explicitly identifies the registrant as Hancock Jaffe Laboratories, Inc.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, or margin figures. However, it discloses the following financial compliance metrics:
- Stock Price: The bid price of common stock closed below $1.00 per share for 30 consecutive business days (violating Listing Rule 5550(a)(2)).
- Stockholders' Equity: The company failed to meet the minimum requirement of $2,500,000 (violating Listing Rule 5550(b)(1)).
Material Changes and Delisting Notice
On April 14, 2020, Nasdaq staff notified the Company that it had not regained compliance with the Bid Price Rule. Consequently, the Company's common stock and warrants are subject to delisting unless a hearing is requested. The Company intends to request a hearing before a Nasdaq Hearings Panel, which will stay any suspension or delisting action pending the outcome.
Outlook, Risks, and Contingencies
Management Action: The Company plans to request a hearing to seek an extension to regain compliance. Nasdaq has suspended the Bid Price Rule compliance deadline through June 30, 2020, and the Equity Rule deadline through October 13, 2020, pending the hearing.
Risks and Uncertainties:
- There is no assurance the Hearings Panel will grant an extension.
- Even if an extension is granted, there is no assurance the Company can regain compliance.
- If delisted, securities will cease to be quoted on Nasdaq and are expected to trade on the over-the-counter market.
- Substantial costs and diversion of personnel resources are anticipated due to these proceedings.
Investor Verification Checklist
- Verify the current status of the Nasdaq Hearings Panel decision regarding the extension request.
- Confirm the current bid price of HJLI common stock to assess compliance with the $1.00 threshold.
- Review the most recent 10-K or 10-Q to determine the exact stockholders' equity balance and liquidity position.
- Monitor for any subsequent filings regarding the outcome of the hearing or a transfer to the over-the-counter market.